Literature DB >> 34419372

Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Lorriana E Leard1, Are M Holm2, Maryam Valapour3, Allan R Glanville4, Sandeep Attawar5, Meghan Aversa6, Silvia V Campos7, Lillian M Christon8, Marcelo Cypel6, Göran Dellgren9, Matthew G Hartwig10, Siddhartha G Kapnadak11, Nicholas A Kolaitis12, Robert M Kotloff13, Caroline M Patterson14, Oksana A Shlobin15, Patrick J Smith10, Amparo Solé16, Melinda Solomon17, David Weill18, Marlies S Wijsenbeek19, Brigitte W M Willemse20, Selim M Arcasoy21, Kathleen J Ramos11.   

Abstract

Tens of thousands of patients with advanced lung diseases may be eligible to be considered as potential candidates for lung transplant around the world each year. The timing of referral, evaluation, determination of candidacy, and listing of candidates continues to pose challenges and even ethical dilemmas. To address these challenges, the International Society for Heart and Lung Transplantation appointed an international group of members to review the literature, to consider recent advances in the management of advanced lung diseases, and to update prior consensus documents on the selection of lung transplant candidates. The purpose of this updated consensus document is to assist providers throughout the world who are caring for patients with pulmonary disease to identify potential candidates for lung transplant, to optimize the timing of the referral of these patients to lung transplant centers, and to provide transplant centers with a framework for evaluating and selecting candidates. In addition to addressing general considerations and providing disease specific recommendations for referral and listing, this updated consensus document includes an ethical framework, a recognition of the variability in acceptance of risk between transplant centers, and establishes a system to account for how a combination of risk factors may be taken into consideration in candidate selection for lung transplantation.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic obstructive pulmonary disease; consensus; cystic fibrosis; emphysema; ethics; interstitial lung disease; lung transplant; pulmonary hypertension; risk factor

Mesh:

Year:  2021        PMID: 34419372      PMCID: PMC8979471          DOI: 10.1016/j.healun.2021.07.005

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   13.569


  335 in total

1.  Extremes of Age Decrease Survival in Adults After Lung Transplant.

Authors:  Carli J Lehr; Eugene H Blackstone; Kenneth R McCurry; Lucy Thuita; Wayne M Tsuang; Maryam Valapour
Journal:  Chest       Date:  2019-08-13       Impact factor: 9.410

2.  The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.

Authors:  Julie Morisset; Eric Vittinghoff; Bo Young Lee; Roberto Tonelli; Xiaowen Hu; Brett M Elicker; Jay H Ryu; Kirk D Jones; Stefania Cerri; Andreina Manfredi; Marco Sebastiani; Andrew J Gross; Brett Ley; Paul J Wolters; Talmadge E King; Dong Soon Kim; Harold R Collard; Joyce S Lee
Journal:  Respir Med       Date:  2017-04-22       Impact factor: 3.415

3.  Organ allocation and utilization in pediatric transplantation.

Authors:  Walter S Andrews; Bartholomew J Kane; Richard J Hendrickson
Journal:  Semin Pediatr Surg       Date:  2017-07-26       Impact factor: 2.754

4.  Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Carli J Lehr; Melissa Skeans; Elliott Dasenbrook; Aliza Fink; Gabriela Fernandez; Albert Faro; Maryam Valapour
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

5.  A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.

Authors:  Hadeel Khadawardi; Marco Mura
Journal:  Respirology       Date:  2016-11-08       Impact factor: 6.424

6.  Lung transplantation for lymphangioleiomyomatosis: single-center Brazilian experience with no chylothorax.

Authors:  T N Machuca; M J Losso; S M Camargo; S M Schio; I A Melo; B Hochhegger; J C Felicetti; J J Camargo
Journal:  Transplant Proc       Date:  2011 Jan-Feb       Impact factor: 1.066

7.  Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.

Authors:  Sumant S Arora; Page Axley; Zunirah Ahmed; Sanjaya K Satapathy; Robert Wong; Young-Fang Kuo; Ashwani K Singal
Journal:  Transpl Int       Date:  2019-03-26       Impact factor: 3.782

8.  Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Authors:  Amparo Solé; Ana A García-Robles; Carlos Jordá; Enrique Cases Viedma; Nuria Mancheño; José Luis Poveda-Andrés; Juan Pablo Reig Mezquida; Javier Pemán
Journal:  Am J Transplant       Date:  2017-12-09       Impact factor: 8.086

9.  Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients.

Authors:  Patricia Álvarez-López; Mar Riveiro-Barciela; Diana Oleas-Vega; Claudia Flores-Cortes; Antonio Román; Manel Perelló; Cristina Berastegui; Lluis Castells; Rafael Esteban; María Buti
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.889

10.  When to consider lung transplantation for COVID-19.

Authors:  Marcelo Cypel; Shaf Keshavjee
Journal:  Lancet Respir Med       Date:  2020-08-25       Impact factor: 30.700

View more
  21 in total

1.  The art of lung transplantation-lessons learnt from one thousand lung transplants.

Authors:  Sameep Sehgal; Chirantan Mangukia; Yoshida Toyoda; Francis Cordova
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-01-23

2.  Deconstructing Silos of Knowledge Around Lung Transplantation to Support Patients: A Patient-specific Search of Scientific Registry of Transplant Recipients Data.

Authors:  Ajay K Israni; David Schladt; Marilyn J Bruin; Sauman Chu; Jon J Snyder; Marshall Hertz; Maryam Valapour; Bertram Kasiske; Warren T McKinney; Cory R Schaffhausen
Journal:  Transplantation       Date:  2022-02-11       Impact factor: 5.385

3.  Low body mass index as a barrier to lung transplant in cystic fibrosis.

Authors:  Ann L Jennerich; Joseph B Pryor; Travis Y Hee Wai; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos
Journal:  J Cyst Fibros       Date:  2021-12-23       Impact factor: 5.527

Review 4.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

5.  Exacerbation of chronic renal failure because of inhaled tobramycin in a lung transplant patient.

Authors:  Víctor M Mora Cuesta; Noelia Borja Vargas; David Iturbe Fernández; Sandra Tello Mena; José M Cifrián Martínez
Journal:  Respir Med Case Rep       Date:  2022-01-22

6.  Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease.

Authors:  Leslie B Tolle
Journal:  Case Rep Pulmonol       Date:  2022-02-15

Review 7.  A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome.

Authors:  Jan Van Slambrouck; Dirk Van Raemdonck; Robin Vos; Cedric Vanluyten; Arno Vanstapel; Elena Prisciandaro; Lynn Willems; Michaela Orlitová; Janne Kaes; Xin Jin; Yanina Jansen; Geert M Verleden; Arne P Neyrinck; Bart M Vanaudenaerde; Laurens J Ceulemans
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

8.  A center experience with lung transplantation for COVID-19 ARDS.

Authors:  Domingo J Franco-Palacios; Lisa Allenspach; Lisa Stagner; Julio Pinto; Kaitlin Olexsey; Eve Sherbin; William Dillon; Daniel Sternberg; Kelly Bryce; Jane Simanovski; Dimitrios Apostolou; Diazo Tanaka; Hassan Nemeh; Zhiqiang Wang; George Alangaden
Journal:  Respir Med Case Rep       Date:  2022-02-01

9.  [Current status of transplantation medicine in the field of heart and lung transplantation].

Authors:  Heidi Niehaus; Axel Haverich; Fabio Ius
Journal:  Z Herz Thorax Gefasschir       Date:  2022-03-08

10.  Towards Biohybrid Lung Development-Fibronectin-Coating Bestows Hemocompatibility of Gas Exchange Hollow Fiber Membranes by Improving Flow-Resistant Endothelialization.

Authors:  Michael Pflaum; Sophie Jurmann; Katherina Katsirntaki; Marisa Mälzer; Axel Haverich; Bettina Wiegmann
Journal:  Membranes (Basel)       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.